Disease · MONDO_0006244

HER2 positive breast carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. HER2 positive breast carcinoma. Diseases, record MONDO_0006244. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006244

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: HER2 positive breast carcinoma; Open Targets
Open Targets ID: MONDO_0006244; Open Targets
Other names: ERBB2 Overexpressing subtype of breast carcinoma, HER2 Overexpressing breast carcinoma, HER2 Overexpressing subtype of breast carcinoma, HER2 Positive breast cancer, Her2-receptor positive breast cancer; Open Targets
Disease Ontology: DOID:0060079; Disease Ontology
NCI Thesaurus: C53556; NCI Thesaurus
Highest stage of its drugs: Approval, for 3 of its 36 drugs, from FDA and TTD; Open Targets

Drugs36

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRASTUZUMAB DERUXTECAN	CHEMBL4297844	Antibody drug conjugate	Approval	TTD	3	2	2	Drugs and targets
TUCATINIB	CHEMBL3989868	Small molecule	Approval	FDA and TTD	2	0	0	Drugs and targets
MARGETUXIMAB	CHEMBL2364649	Antibody	Approval	TTD	1	0	0	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Preapproval	TTD	5	4	4	Drugs and targets
TRASTUZUMAB EMTANSINE	CHEMBL1743082	Antibody drug conjugate	Phase 3	TTD	1	0	0	Drugs and targets
ZENIDOLOL	CHEMBL513389	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets

1 to 10 of 36

See all 36 drugs

Targets106

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ERBB2	Epidermal growth factor receptor	8	Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor	Approval	https://conductscience.org/library/genes/2064	Drugs and targets
TUBA1A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	7	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 106

See all 106 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02066532	Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	Phase 1/2	32	2023-08-24	Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer	RUXOLITINIB, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03424005	A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer	Phase 1/2	1,132		Metastatic Breast Cancer	ABEMACICLIB, ATEZOLIZUMAB, ATIRMOCICLIB, BEVACIZUMAB, CAPECITABINE, CARBOPLATIN, EMPAGLIFLOZIN, ERIBULIN, FULVESTRANT, GEMCITABINE, INAVOLISIB, IPATASERTIB, LADIRATUZUMAB VEDOTIN, LETROZOLE, METFORMIN, PALBOCICLIB, RIBOCICLIB, SACITUZUMAB GOVITECAN, SELICRELUMAB, TOCILIZUMAB, TRASTUZUMAB DERUXTECAN	Its record names the disease	ClinicalTrials.gov
NCT04302441	A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy	Phase 2	550		Breast Cancer	CAPECITABINE, TRASTUZUMAB, VINORELBINE	Its record names the disease	ClinicalTrials.gov
NCT05978648	Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy	Phase 2	116		Breast Neoplasms	CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB, TRILACICLIB	Its record names the disease	ClinicalTrials.gov
NCT05301530	Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.	Phase 1	50		Breast Cancer Metastatic, Breast Cancer Female, Breast Cancer Recurrent	DOCETAXEL, TRASTUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT06797622	Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer	Phase 2	50		Breast Cancer, Metastatic Breast Cancer	TRASTUZUMAB DERUXTECAN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials20

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23764181	RESULT	1	PubMed
20038734	RESULT	1	PubMed
19916733	RESULT	1	PubMed
19884557	RESULT	1	PubMed
18515736	RESULT	1	PubMed
17033039	RESULT	1	PubMed
16736568	RESULT	1	PubMed
16597163	RESULT	1	PubMed
16149088	RESULT	1	PubMed
15911866	RESULT	1	PubMed

1 to 10 of 20

See all 20 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006244

GET https://conductscience.org/api/diseases/v1/MONDO_0006244/drugs?page=2

API reference For AI assistants